CTLA4 and glioblastoma: However, the adjuvant anti-CTLA4 antibody ipilimumab combined with TMZ after surgery and chemoradiotherapy did not result in a survival benefit for newly diagnosed GBM patients (mOS, 22.7 vs. 26.4 months; mPFS, 10.9 vs. 12.5 months) [42].